glycogen and Triple-Negative-Breast-Neoplasms

glycogen has been researched along with Triple-Negative-Breast-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for glycogen and Triple-Negative-Breast-Neoplasms

ArticleYear
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.
    Journal of experimental & clinical cancer research : CR, 2023, Jun-06, Volume: 42, Issue:1

    Hypoxia-induced glycogen turnover is implicated in cancer proliferation and therapy resistance. Triple-negative breast cancers (TNBCs), characterized by a hypoxic tumor microenvironment, respond poorly to therapy. We studied the expression of glycogen synthase 1 (GYS1), the key regulator of glycogenesis, and other glycogen-related enzymes in primary tumors of patients with breast cancer and evaluated the impact of GYS1 downregulation in preclinical models.. mRNA expression of GYS1 and other glycogen-related enzymes in primary breast tumors and the correlation with patient survival were studied in the METABRIC dataset (n = 1904). Immunohistochemical staining of GYS1 and glycogen was performed on a tissue microarray of primary breast cancers (n = 337). In four breast cancer cell lines and a mouse xenograft model of triple-negative breast cancer, GYS1 was downregulated using small-interfering or stably expressed short-hairpin RNAs to study the effect of downregulation on breast cancer cell proliferation, glycogen content and sensitivity to various metabolically targeted drugs.. High GYS1 mRNA expression was associated with poor patient overall survival (HR 1.20, P = 0.009), especially in the TNBC subgroup (HR 1.52, P = 0.014). Immunohistochemical GYS1 expression in primary breast tumors was highest in TNBCs (median H-score 80, IQR 53-121) and other Ki67-high tumors (median H-score 85, IQR 57-124) (P < 0.0001). Knockdown of GYS1 impaired proliferation of breast cancer cells, depleted glycogen stores and delayed growth of MDA-MB-231 xenografts. Knockdown of GYS1 made breast cancer cells more vulnerable to inhibition of mitochondrial proteostasis.. Our findings highlight GYS1 as potential therapeutic target in breast cancer, especially in TNBC and other highly proliferative subsets.

    Topics: Animals; Cell Line, Tumor; Glycogen; Glycogen Synthase; Humans; Mice; RNA, Messenger; RNA, Small Interfering; Triple Negative Breast Neoplasms; Tumor Microenvironment

2023
Activation of glycogenolysis and glycolysis in breast cancer stem cell models.
    Biochimica et biophysica acta. Molecular basis of disease, 2020, 10-01, Volume: 1866, Issue:10

    Topics: Cell Hypoxia; Cell Line, Tumor; Female; Gluconeogenesis; Glucose; Glycogen; Glycogenolysis; Glycolysis; Humans; Indoles; Neoplastic Stem Cells; Oxidative Phosphorylation; Propanols; Triple Negative Breast Neoplasms; Tumor Microenvironment

2020